Disruption of mitochondrial transport, distribution and dynamics arises early in the progression of multiple neurodegenerative disorders caused by environmental and genetic factors, and could be a causative factor in neuronal failure. However, the molecular mechanisms of mitochondrial trafficking inhibition and biomarkers of early mitochondrial dysfunction are undefined. Lack of such knowledge limits development of tools for early diagnosis, monitoring disease progression, and design of efficient therapeutic strategies for neurodegenerative disorders. The objective in this application is using advance technologies to develop an integral panel of mitochondrial/metabolomic biomarkers for early diagnosis of mitochondrial dysfunction in neurodegenerative disorders caused by genetic and environmental factors and to determine molecular mechanism of mitochondrial trafficking inhibition that could be common for multiple diseases. The central hypothesis is that genetic and environmental stressors initiate mitochondrial dysfunction through the common mechanism that involves disruption of mitochondrial dynamics that reflects on and could be detected early by analyzing dynamic alterations in metabolomic signatures and metabolic networks. The rationale for the proposed research is that establishment of mitochondrial and metabolomic signatures as a panel of candidate biomarkers will allow validation in a larger cohort of patients whether these biomarkers could be used for early diagnosis and prediction/monitoring of disease progression. Guided by strong preliminary data, this hypothesis will be tested by pursuing four specific aims: 1) Establish a correlation algorithm between altered parameters of mitochondrial dynamics and signature metabolomic biomarkers in development of mitochondrial dysfunction in neurodegeneration, 2) Validate the use of integral biomarkers of early mitochondrial dysfunction for monitoring the disease progression in trans- genic animal models for AD, HD and PD, and environmental toxicity in vivo, 3) Determine the molecular mechanism of mitochondrial trafficking inhibition induced by environmental and genetic stressors, and 4) Establish the relationship between integral mitochondrial biomarkers and progression of disease in AD, HD and PD patients. Advanced biochemical and cell biology techniques will be applied and combined with the utilization of analytical metabolomic platforms based on 18O-assisted GC/MS, LC/MS/MS, 1H NMR and 18O-assisted 31P NMR technologies to establish the relationship between altered mitochondrial dynamics and metabolomic profiles and global changes in energetic and metabolic signaling circuits in neurons, tissue and body fluids from transgenic animal models and human patients that are associated with Mito dysfunction caused by genetic and environmental stressors.

Public Health Relevance

Mitochondrial dysfunction has been shown to play a central role in progression of multiple neurodegenerative disorders caused by environmental stress and genetic factors. Lack of the under- standing of the molecular mechanisms underlying mitochondrial dysfunction precludes the development of efficient strategies for early diagnosis, prevention and treatment. The proposed study will determine the mechanism by which different genetic and environmental stressors cause mitochondrial dysfunction and will identify relevant metabolomic biomarkers. This study will facilitate understanding of the molecular mechanisms underlying neurodegeneration and promote the development of tools for drug design, diagnosis and disease monitoring.

Agency
National Institute of Health (NIH)
Institute
National Institute of Environmental Health Sciences (NIEHS)
Type
Research Project (R01)
Project #
1R01ES020715-01
Application #
8216043
Study Section
Special Emphasis Panel (ZES1-LWJ-J (MI))
Program Officer
Shaughnessy, Daniel
Project Start
2011-09-20
Project End
2016-06-30
Budget Start
2011-09-20
Budget End
2012-06-30
Support Year
1
Fiscal Year
2011
Total Cost
$305,930
Indirect Cost
Name
Mayo Clinic, Rochester
Department
Type
DUNS #
006471700
City
Rochester
State
MN
Country
United States
Zip Code
55905
Podratz, Jewel L; Lee, Han; Knorr, Patrizia et al. (2017) Cisplatin induces mitochondrial deficits in Drosophila larval segmental nerve. Neurobiol Dis 97:60-69
Tönnies, Eric; Trushina, Eugenia (2017) Oxidative Stress, Synaptic Dysfunction, and Alzheimer's Disease. J Alzheimers Dis 57:1105-1121
Trushina, Eugenia (2016) A shape shifting organelle: unusual mitochondrial phenotype determined with three-dimensional electron microscopy reconstruction. Neural Regen Res 11:900-1
Pistollato, Francesca; Ohayon, Elan L; Lam, Ann et al. (2016) Alzheimer disease research in the 21st century: past and current failures, new perspectives and funding priorities. Oncotarget 7:38999-39016
Rizvi, Sumera; Yamada, Daisaku; Hirsova, Petra et al. (2016) A Hippo and Fibroblast Growth Factor Receptor Autocrine Pathway in Cholangiocarcinoma. J Biol Chem 291:8031-47
Zhang, Liang; Zhang, Song; Maezawa, Izumi et al. (2015) Modulation of mitochondrial complex I activity averts cognitive decline in multiple animal models of familial Alzheimer's Disease. EBioMedicine 2:294-305
Yue, M; Hinkle, K M; Davies, P et al. (2015) Progressive dopaminergic alterations and mitochondrial abnormalities in LRRK2 G2019S knock-in mice. Neurobiol Dis 78:172-95
Klosinski, Lauren P; Yao, Jia; Yin, Fei et al. (2015) White Matter Lipids as a Ketogenic Fuel Supply in Aging Female Brain: Implications for Alzheimer's Disease. EBioMedicine 2:1888-904
Snyder, Heather M; Carrillo, Maria C; Grodstein, Francine et al. (2014) Developing novel blood-based biomarkers for Alzheimer's disease. Alzheimers Dement 10:109-14
Trushina, Eugenia; Canaria, Christie A; Lee, Do-Yup et al. (2014) Loss of caveolin-1 expression in knock-in mouse model of Huntington's disease suppresses pathophysiology in vivo. Hum Mol Genet 23:129-44

Showing the most recent 10 out of 15 publications